Hiroki Kobayashi, Yoshihiro Nakamura, Masanori Abe, Akiyo Tanabe, Masakatsu Sone, Takuyuki Katabami, Isao Kurihara, Takamasa Ichijo, Mika Tsuiki, Shoichiro Izawa, Norio Wada, Takashi Yoneda, Katsutoshi Takahashi, Kouichi Tamura, Yoshihiro Ogawa, Nobuya Inagaki, Koichi Yamamoto, Hiromi Rakugi, Mitsuhide Naruse
In Japan, the standard method for measuring plasma aldosterone concentration (PAC) for primary aldosteronism (PA) diagnosis was changed from radioimmunoassay (RIA) to a novel chemiluminescent enzyme immunoassay (CLEIA). The purpose of this study is to simulate the possible impact of the change on PA diagnosis. This retrospective study assessed 2,289 PA patients. PACs measured by conventional RIA were transformed to estimated PACs (CLEIA) as follows: RIA (pg/mL) = 1.174 × CLEIA (pg/mL) + 42.3. We applied the estimated PAC (CLEIA) to the conventional cut-off of aldosterone-to-renin activity ratio ≥200 for screening and captopril challenge test (CCT) and PAC ≥60 pg/mL for saline infusion test (SIT)...
February 16, 2023: Endocrine Journal